Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists, ensuring independent content production [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Amendment reduces and simplifies royalty structure on Teverelix® from ~4% to 2% while preserving global rights and IP control The Company is developing Teverelix® as a first in class market product for Acute Urinary Retention Relapse prevention (AURr) and best in class for prostate cancer patients with high CV risk collectively representing ~US$6 billion in potential market opportunity PHILADELPHIA, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precisio ...

The Company enters 2026 with Multiple Phase 2 Catalysts, AI-enabled drug development strategy, and regulatory optionality as SKNJCT-003 study approaches database lock, topline clinical data readout and partnering readinessPHILADELPHIA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to an ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

The Company’s abstract, Evaluation of Teverelix in Healthy Female Volunteers, has been accepted for presentation at American Association of Clinical Endocrinology (AACE) Annual meeting 2026PHILADELPHIA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that detailed clinical dat ...

Core Insights - Medicus Pharma Ltd. is set to present at the Biotech Showcase 2026, highlighting its focus on advancing clinical development programs for innovative therapeutics [1][2] Company Strategy - The company's strategy involves advancing select programs through Phase 2 proof-of-concept and pursuing licensing or strategic partnerships with established pharmaceutical companies for late-stage development and commercialization [5] - Medicus aims to assemble decision-grade clinical, regulatory, and operational data packages aligned with its out-licensing strategy as data matures across its programs [5] Clinical Development Updates - The SkinJect™ Phase 2 program, designed to non-invasively treat basal cell carcinoma (BCC), has achieved execution milestones, including the completion of enrollment of 90 patients in a randomized, double-blind, placebo-controlled study [6][7] - Topline decision-grade Phase 2 results are expected to be reported in the first quarter of 2026, with plans for an End-of-Phase 2 meeting with the FDA in the first half of 2026 [8][31] - Interim findings from the study indicated greater than 60% clinical clearance in an exploratory analysis [9] Regulatory and Geographic Expansion - Medicus has expanded the clinical and regulatory footprint of SkinJect™ to support development and partnering readiness, including approvals in the UK and the UAE for ongoing studies [10][30] - The FDA provided positive feedback regarding the potential use of the 505(b)(2) regulatory pathway for SkinJect™ [11] Collaboration and Partnerships - Medicus has entered a non-binding letter of intent with Reliant AI Inc. to develop an AI-driven clinical data analytics platform aimed at supporting capital-efficient clinical development [15][32] - The company is exploring co-development opportunities with Helix Nanotechnologies for thermostable infectious disease vaccines [17][23] Pipeline Expansion - The acquisition of Antev Limited has added Teverelix, a next-generation GnRH antagonist targeting advanced prostate cancer patients, to Medicus's pipeline [18][24] - Teverelix has shown promising results in previous clinical trials, including a Phase 2a study demonstrating a 97.5% probability of achieving castration levels of testosterone suppression [26] Patient Access Initiatives - Medicus is collaborating with the Gorlin Syndrome Alliance to pursue an Expanded Access IND program for SkinJect™, aiming to provide access to patients with multiple or inoperable BCCs [19][29]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Core Viewpoint - Medicus Pharma has completed patient enrollment in its SkinJect clinical trial, marking a significant milestone in the development of a noninvasive treatment for basal cell carcinoma, the most common skin cancer [1][4]. Company Overview - Medicus Pharma is advancing its clinical development program for SkinJect, a novel treatment targeting non-melanoma skin diseases, particularly basal cell carcinoma [3][4]. - The company has been working on this project since the fall of 2023, with patient recruitment starting in August 2024 [4]. Clinical Trial Details - The clinical trial has enrolled 90 patients across nine sites in the United States [1][4]. - The company aims to present topline data in Q1 2026 and plans to sync with the FDA for an end-of-phase-two meeting in the first half of next year [4][8]. Treatment Methodology - SkinJect utilizes uniquely designed microneedle arrays developed from Carnegie Mellon and the University of Pittsburgh, allowing for direct application of a chemotherapeutic agent, doxorubicin, to the cancer site [6]. - This method is intended to trigger an immunogenic response and effectively kill cancer cells [6]. Market Context - Non-melanoma skin diseases, especially basal cell carcinoma, account for 5 million new cases annually in the United States and over 30 million globally [5]. - Traditional treatments like Mohs surgery are expensive and painful, highlighting the need for a more cost-effective and aesthetically pleasing alternative [5][7]. Future Outlook - The company is optimistic about the upcoming topline data and the potential for a Priority Review Voucher from the FDA, which could expedite the new drug application timeline by 10-12 months [8][9]. - The NDA is expected to be filed in late 2027 or early 2028, aligning with the company's positive momentum [8][9].

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...